

CURRICULUM VITAE

PERSONAL DATA

Name: Michael Asger Andersen
 Mail: michael.asger.andersen@regionh.dk
 Phone: +45 31 77 08 56
 ORCID: 0000-0001-9729-9974
 Website: <https://masger.github.io>

EDUCATION

2008–2015 MD, University of Copenhagen, Denmark
 2016–2021 PhD, University of Copenhagen, Denmark (January 15th, 2021)
 2023–2027 Clinical specialization in clinical pharmacology (expected October 1st, 2027)
 2026 BRIDGE Translational Excellence Programme Omics Courses, University of Copenhagen

POSITIONS

2015–2016 Resident (KBU), Dep. of Infectious Diseases and Dep. of Urology, Herlev Hospital
 2016–2020 Research fellow and clinical assistant, Dep. of Hematology, Rigshospitalet
 2020–2021 Postdoc, CLL-LAB, Dep. of Hematology, Rigshospitalet
 2020–2021 Resident, Dep. of Infectious Disease Epidemiology & Prevention, Statens Serum Institut
 2021–2023 Resident, Dep. of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital
 2023–2024 Senior Medical Doctor, Cardiovascular Clinical Development, Novo Nordisk (specialty training rotation in clinical pharmacology)
 2024–2025 Specialty Registrar, Dep. of Endocrinology, Herlev Hospital
 2025–2026 Specialty Registrar, Dep. of Clinical Biochemistry and Genomic Medicine, Rigshospitalet
 2026– Specialty Registrar, Dep. of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital

SCIENTIFIC AWARDS & HONORS

2017 Best abstract award, International Workshop on Chronic Lymphocytic Leukemia (IWCLL), New York
 2018 Best scientific visualization, ARTIS, University of Copenhagen
 2019 Best abstract award, IWCLL, Edinburgh
 2019 Audience award, FYF annual poster competition, Rigshospitalet
 2022 Best poster, Lassen-dagen, Bispebjerg and Frederiksberg Hospital
 2023 Second best oral presentation, Lassen-dagen, Bispebjerg and Frederiksberg Hospital
 2024 Second best oral presentation, Danish Society of Clinical Pharmacology (DSKF) annual meeting
 2026 Best poster award, 40th Nordic Congress in Clinical Biochemistry, Aarhus

SCIENTIFIC FOCUS AREAS

My research focuses on cardiovascular and oncological pharmacotherapy, centered on the investigator-initiated multicenter SAMSON-2 trial. As sponsor and principal investigator, I lead this randomized N-of-1 trial platform to systematically evaluate statin-associated muscle symptoms and overcome drug intolerance. In parallel, I lead the TDM-VISION project, establishing therapeutic drug monitoring algorithms for targeted oral therapies in chronic lymphocytic leukemia. Methodologically, my work bridges prospective clinical trials, nationwide Danish health registries, and clinical pharmacogenetics to translate precision medicine into direct bedside decisions.

BIBLIOMETRY

46 peer-reviewed original articles, reviews and guidelines (13 as first author, 5 as last author, 28 as co-author; plus 1 case report).
 20 articles published within the last 3 full years and 2026.
 Articles published in leading international journals including *Circulation*, *Nature Communications*, *Leukemia*, *Haematologica*, *Clinical Cancer Research*, and *Clinical Infectious Diseases*.
 Citations: 1,112 (1,012 since 2021), H-index: 18 (17 since 2021), i10-index: 27 (26 since 2021; Source: Google Scholar, 29 October 2026).

GRANTS

2016	PERSIMUNE Research Grant	DKK 0.5M
2017	Research Foundation of Rigshospitalet, PhD grant	DKK 1.8M
2018	AP Møller Research Foundation	DKK 0.1M
2024	Danish Cancer Society (TDM-VISION, PI)	DKK 2.3M
2025	Region Hovedstaden Research Fund	DKK 0.6M
2025	Bispebjerg Hospital Internal Research Fund	DKK 0.32M
2026	Hørslev-Fonden	DKK 0.3M
2026	BRIDGE Translational Excellence Programme Omics Courses, KU	Course grant

Multiple project and collaborative grants secured as co-PI.

SUPERVISION

2018–2022	Primary supervisor for 4 Master theses and 2 Bachelor projects, University of Copenhagen.
2024–now	PhD co-supervisor, TDM-VISION project (ongoing).

INVITED TALKS

2018	Dagens Medicin, ASH Highlights
2019	Nordic CLL Study Group, Danish health registries in hematology research
2024	Danish Society of Clinical Pharmacology (DSKF) Annual Meeting
2026	Lægeforeningen (Danish Medical Association), Pharmacogenetics in clinical practice

EDITOR

2023–now	Review Editor, Frontiers in Epidemiology (Epidemiology of Chronic Diseases and Prevention)
----------	--

REVIEWER

Journals:	Recurrent reviewer for European Heart Journal, Basic & Clinical Pharmacology & Toxicology, Leukemia, Clinical Pharmacology & Therapeutics, Communications Medicine, and Ugeskrift for Læger.
Guidelines:	Reviewer for NIH Medical Genetics Summaries (Simvastatin Therapy and SLCO1B1 Genotype).
Theses:	External Examiner (Censor) for 10 Bachelor and Master theses in Medicine, University of Copenhagen (2026); External Examiner for 2 Master theses, Master in Personalized Medicine, University of Copenhagen and Technical University of Denmark (2026).

COMMITTEE WORK

2017–2022	Webmaster and Secretary, Nordic CLL Study Group
2022–now	Member, Clinical Pharmacogenetics Implementation Consortium (CPIC)
2022–now	Member, Pharmacogenomics Global Research Network (PGRN)
2023–2025	Board Member, Danish Society for Personalized Medicine (DSPM)
2025–now	Chair, Danish Society for Personalized Medicine (DSPM)
2026–now	Auditor, Danish Society of Clinical Pharmacology (DSKF)
2026–now	Appointed National Expert (1 of 3), Danish National Strategy for Personalized Medicine

TEACHING

- 2008–2015 Lectures in medical IT and health informatics for 1st semester medical students, University of Copenhagen (ca. 150–200 students per semester).
- 2020–2021 Invited lecturer, Digital Health and Data (Module 1), University of Copenhagen (ca. 50 participants per year).
- 2021–2022 Instructor in biostatistics, epidemiology, and R programming (SEMS), 3rd semester MSc Medicine, University of Copenhagen (5 ECTS, ca. 20 students per class, 2 hours weekly).
- 2021–2023 Co-organizer and instructor, Clinical Pharmacology CRASH Course 1 & 2, Bispebjerg and Frederiksberg Hospital (ca. 50 participants per course, 4 times per semester).
- 2021–2025 Annual lecture, Danish Health Registers for Clinical Research (ca. 20 students).

INTERNATIONAL RELATIONSHIPS

I collaborate actively with international consortia in cardiovascular pharmacogenomics and hematology. I am a Work Package collaborator in the European SPOCK Trial, investigating CYP2C19-guided clopidogrel therapy across European centers, and participate in COST Action CardioPharmGeneNet. In international guideline development, I serve as a working group member for the NAT2 guideline in the Clinical Pharmacogenetics Implementation Consortium (CPIC) and contribute to the Pharmacogenomics Global Research Network (PGRN).

LEADERSHIP EXPERIENCE

As Chair of the Danish Society for Personalized Medicine (DSPM) and appointed National Expert under the Danish National Strategy for Personalized Medicine, I lead national initiatives connecting academic research, clinical genetics, and regulatory implementation. Scientifically, I serve as Sponsor and Principal Investigator for the multicenter SAMSON-2 trial and PI for the TDM-VISION project, overseeing research budgets totaling DKK 5.95M and supervising multidisciplinary project teams across clinical pharmacology, oncology, and laboratory biochemistry.

PUBLICATION LIST

I. ORIGINAL SCIENTIFIC PUBLICATIONS (PEER REVIEWED)

1. **Andersen MA**, Vojdeman FJ, Andersen MK, Brown Pde N, Geisler CH, Weis Bjerrum O, Niemann CU. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. *Leuk Lymphoma* 2016;57(7):1592-9.
2. Johansen MM, **Andersen MA**, Grønbaek K, Hansen JW. Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment: A single center study. *Eur J Haematol* 2018;101(5):595-603.
3. **Andersen MA**, Bjerrum OW, Ranjan A, Skov V, Kruse TA, Thomassen M, ..., Christensen K. Myeloproliferative Neoplasms in Danish Twins. *Acta Haematol* 2018;139(3):195-198.
4. Brieghel C, Kinalis S, Yde CW, Schmidt AY, Jønson L, **Andersen MA**, ..., Niemann CU. Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact in the era of targeted therapy. *Haematologica* 2019;104(4):789-796.
5. **Andersen MA**, Moser CE, Lundgren J, Niemann CU. Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. *Leukemia* 2019;33(3):662-670. (Erratum: *Leukemia* 2020;34(10):2817-2818).
6. Hleuhel MH, Ben-Dali Y, Da Cunha-Bang C, Brieghel C, Clasen-Linde E, Niemann CU, **Andersen MA**. Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study. *BMJ Open* 2019;9(3):e023566.
7. Agius R, Brieghel C, **Andersen MA**, Pearson AT, Ledergerber B, Cozzi-Lepri A, ..., Niemann CU. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. *Nat Commun* 2020;11(1):363.
8. Aarup K, Rotbain EC, Enggaard L, Pedersen RS, Bergmann OJ, Thomsen RH, ..., Niemann CU. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. *Eur J Haematol* 2020;105(5):646-654.
9. Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, Brieghel C, Poulsen CB, Clasen-Linde E, ..., **Andersen MA**. Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. *Leuk Lymphoma* 2020;61(6):1435-1444.
10. Brieghel C, da Cunha-Bang C, Yde CW, Schmidt AY, Kinalis S, Nadeu F, ..., Niemann CU. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome. *Clin Cancer Res* 2020;26(6):1507-1515.
11. **Andersen MA**, Rostgaard K, Niemann CU, Hjalgrim H. Antimicrobial use before chronic lymphocytic leukemia: a retrospective cohort study. *Leukemia* 2021;35(3):747-751.
12. Brieghel C, Aarup K, Torp MH, **Andersen MA**, Yde CW, Tian X, ..., Niemann CU. Clinical and Biological Implications of Multi-Hit Versus Single-Hit TP53 Inactivation in Chronic Lymphocytic Leukemia. *Clin Cancer Res* 2021;27(16):4531-4538.
13. **Andersen MA**, Niemann CU, Rostgaard K, Dalby T, Sørrig R, Weinberger DM, Hjalgrim H, Harboe ZB. Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study. *Clin Infect Dis* 2021;72(3):463-471.
14. Rotbain EC, Rostgaard K, **Andersen MA**, Da Cunha-Bang C, Niemann CU, Frederiksen H, Hjalgrim H. Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia. *Clin Epidemiol* 2021;13:1155-1165.
15. da Cunha-Bang C, Rostgaard K, **Andersen MA**, Rotbain EC, Grønbaek K, Frederiksen H, Niemann CU, Hjalgrim H. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. *Br J Haematol* 2021;193(2):339-345.
16. Davidsson OB, Olofsson IA, Kogelman LJ, **Andersen MA**, Rostgaard K, Hjalgrim H, Olesen J, Hansen TF. Twenty-five years of triptans - a nationwide population study. *Cephalalgia* 2021;41(8):894-904.
17. Svanberg R, MacPherson C, Zucco A, Agius R, Faitova T, **Andersen MA**, ..., Ostrowski SR. Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients. *Commun Med (Lond)* 2022;2:114. (Author Correction: *Commun Med* 2023;3:15).
18. Staerk-Østergaard J, Kirkeby C, Christiansen LE, **Andersen MA**, Møller CH, Voldstedlund M, Denwood MJ. Evaluation of diagnostic test procedures for SARS-CoV-2 using latent class models. *J Med Virol* 2022;94(10):4754-4761.
19. Brieghel C, Galle V, Agius R, da Cunha-Bang C, **Andersen MA**, Vlummens P, ..., Niemann CU. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. *Eur J Haematol* 2022;108(5):369-378.
20. **Andersen MA**, Grand MK, Brieghel C, Siersma V, Andersen CL, Niemann CU. Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia. *Commun Med (Lond)* 2022;2:50.
21. Nielsen KF, Moustsen-Helms IR, Schelde AB, Gram MA, Emborg HD, Nielsen J, ..., Valentiner-Branth P. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish

nationwide study. *PLoS Med* 2022;19(11):e1004037.

22. Rotbain EC, Allmer C, Rostgaard K, **Andersen MA**, Vainer N, da Cunha-Bang C, ..., Niemann CU. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia. *Am J Hematol* 2023;98(8):1236-1245.
23. Roen A, Terrones C, Bannister W, Helleberg M, **Andersen MA**, Niemann CU, ..., Lundgren J. Increased incidence rates of positive blood cultures shortly after chemotherapy compared to radiotherapy among individuals treated for solid malignant tumours. *Infection* 2023;51(1):147-157.
24. Vainer N, Aarup K, **Andersen MA**, Wind-Hansen L, Nielsen T, Frederiksen H, ..., Rotbain EC. Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia. *Br J Haematol* 2023;201(5):874-886.
25. **Andersen MA**, Helms Andreasen A, Evi Bang L, Jimenez-Solem E, Petersen TS. A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia. *Commun Med (Lond)* 2024;4(1):193.
26. **Andersen MA**, Gregersen R, Petersen TS, Wang JN, Petersen J, Jimenez-Solem E. Association Between First-time Neurologic Events and Metronidazole Treatment: A Case-time Control Study. *Clin Ther* 2024;46(4):307-312.
27. **Andersen MA**, Jensen TL, Petersen TS. Data Resource Profile: The Danish National Hospital Medicine Register. *Pharmacoepidemiol Drug Saf* 2024;33(11):e70054.
28. Packness E, Davidsson OB, Rostgaard K, **Andersen MA**, Rotbain EC, Niemann CU, Brieghel C, Hjalgrim H. Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma. *Br J Cancer* 2024;131(7):1186-1194.
29. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, **Andersen MA**, Johansson KS, ..., Horwitz H. Cardiovascular Disease in Anabolic Androgenic Steroid Users. *Circulation* 2025;151(12):828-834.
30. Brieghel C, Lacoppidan T, Packness E, Frederiksen CM, Werling M, **Andersen MA**, ..., Niemann CU. Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer. *Hemasphere* 2025;9(7):e70172.
31. Christensen LWS, Boas AK, Clausen E, Koch NE, Walls AB, Nørgaard LS, ..., Houliind MB. Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients. *Br J Clin Pharmacol* 2026;10.1002/bcp.70799.

II. CLINICAL GUIDELINES & CONSORTIA (PEER REVIEWED)

32. Eadon MT, Hein DW, **Andersen MA**, Chapman AB, Cooper-DeHoff RM, Desta Z, ..., Agúndez JAG. Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy. *Clin Pharmacol Ther* 2025;118(6):1430-1436.

III. SCIENTIFIC REVIEWS (PEER REVIEWED)

33. Del Giudice I, Cappelli LV, Delgado J, Niemann CU, **Andersen MA**, Rotbain EHC, ..., Foà R. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature. *Br J Haematol* 2023;201(2):353-356.
34. Karlsen APH, Sunde PB, Olsen MH, Laigaard J, Folkersen C, Tran TXM, ..., Mathiesen O. Opioids and personalized analgesia in the perioperative setting: A protocol for five systematic reviews. *Acta Anaesthesiol Scand* 2024;68(10):1573-1580.
35. Erichsen PA, Dalhoff K, **Andersen MA**. Should high-dose N-acetylcysteine be given in cases of massive paracetamol overdoses: A narrative review. *Basic Clin Pharmacol Toxicol* 2024;135(3):285-294.
36. Korsholm C, Bülow C, Christensen M, Dalhoff K, Feinberg JB, Lund TM, ..., **Andersen MA**. Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review. *Leuk Lymphoma* 2025;66(2):229-239.
37. Breining P, Bork CS, Bartels LE, **Andersen MA**. Statin-induced muscle symptoms. *Ugeskr Laeger* 2025;187(43):V03250169.
38. Kjartansdóttir SP, Folkersen C, Rasmussen IH, Sunde PB, Saito A, Maagaard M, ..., Karlsen APH. Pharmacogenetic Predictors of Postoperative Opioid-Related Adverse Events: A Systematic Review. *Basic Clin Pharmacol Toxicol* 2026;138(2):e70154.
39. Bentsen MS, Bundgaard JS, Brøns N, Rand SA, **Andersen MA**, Rosasing M, ..., Ostrowski SR. Clinical pharmacogenetics and the use of biobanks. *Ugeskr Laeger* 2026;188(37):V01260062.

IV. SHORT REPORTS, COMMENTARIES & OTHER PEER REVIEWED PUBLICATIONS

40. **Andersen MA**, Nielsen RT. Spontaneous renal rupture of fornix due to obstructing urethral stone. *Ugeskr Laeger* 2017;179(36):V02170114.
41. **Andersen MA**, Niemann CU. Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark.

Haematologica 2018;103(7):e330.

42. **Andersen MA**, Eriksen CT, Brieghel C, Bicciler JL, Cunha-Bang CD, Helleberg M, Niemann CU. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. *Haematologica* 2018;103(7):e300-e303.
43. **Andersen MA**, Valentin R, Dissing Sjö L, Borgwardt L, Schmiegelow K, Andersen MK, ..., Niemann CU. Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. *Acta Oncol* 2020;59(12):1547-1551.
44. Egholm GJ, **Andersen MA**, Andersen CL, Frederiksen H, Bjerrum OW, Niemann CU. Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival. *Br J Haematol* 2021;192(3):e81-e84.
45. Vojdeman FJ, Helby J, Pedersen LB, Brieghel C, **Andersen MA**, Nordestgaard BG, Bojesen SE, Niemann CU. Chronic lymphocytic leukaemia clones are detectable decades before diagnosis. *Br J Haematol* 2022;196(3):784-787.
46. Damkier P, **Andersen MA**. Temporary Like Achilles: Pre-emptive germline pharmacogenetic testing. *Basic Clin Pharmacol Toxicol* 2023;133(4):397-399.
47. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, **Andersen MA**, Johansson KS, ..., Horwitz H. Response by Windfeld-Mathiasen et al to Letter Regarding Article, "Cardiovascular Disease in Anabolic Androgenic Steroid Users". *Circulation* 2025;152(16):e296-e297.